月経困難症治療薬市場：タイプ、治療法、流通チャネル、エンドユーザー別-2025-2030年世界予測

月経困難症治療薬市場は、2023年に71億6,000万米ドルと評価され、2024年には78億米ドルに達すると予測され、CAGR 8.98％で成長し、2030年には130億9,000万米ドルに達すると予測されています。

月経困難症治療薬市場には、世界の女性人口のかなりの部分を苦しめている月経痛を緩和することを目的とした、医薬品、機器、代替療法の範囲が含まれています。これらの治療の必要性は、月経困難症の高い有病率と、生活の質、生産性、精神的健康への影響によってもたらされます。非ステロイド性抗炎症薬（NSAIDs）のような市販の鎮痛剤から、ホルモン療法、経皮的電気神経刺激（TENS）や鍼治療のような新しい介入まで、用途は多岐にわたる。主なエンドユーザーには、病院、診療所、自宅での緩和策を求める個人消費者が含まれます。市場の成長を後押ししているのは、認知度の向上、ヘルスケアへのアクセスの改善、個別化医療を可能にするバイオテクノロジーの進歩です。非侵襲的な代替医療への関心の高まりは、治療範囲をさらに広げています。とはいえ、従来の治療法の副作用、未発達地域における認識不足、規制上のハードルといった課題が大きな障壁となっています。市場参入企業は、神経刺激やウェアラブル技術における画期的なアプリケーションのような、より低侵襲でより効果的なソリューションの革新的研究を通じてアンメットニーズに対応しながら、こうした制約を乗り越えていかなければならないです。女性の健康を支援する政府の政策と研究開発への投資の増加は、大きなビジネスチャンスをもたらします。このような機会を捉えるための推奨事項としては、教育活動を強化すること、十分なサービスを受けていない市場に焦点を当てること、ヘルスケアプロバイダーとのコラボレーションを促進し、製品の普及と信頼の裏付けを図ることなどが挙げられます。また、自然療法やバイオテクノロジーによる副作用のない治療法の開発を強調することで、消費者の関心を集めることもできると思われます。市場の特性に関する考察から、競合情勢は科学の進歩とともに進化していること、消費者の嗜好がホリスティックな健康アプローチにシフトしていること、医薬品とテクノロジーの進歩を組み合わせた統合ソリューションが重視されるようになっていることが明らかになった。革新の機が熟した主要分野には、リアルタイムモニタリングによるデジタルヘルス統合や、最小限の介入と手頃な価格という嗜好に沿った代替疼痛管理技術の探求などがあります。

市場力学：急速に進化する月経困難症治療薬市場の主要市場インサイトを公開

月経困難症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 月経困難症の有病率と効果的な治療オプションの必要性
  • 女性のリプロダクティブ・ヘルス（性と生殖に関する健康）に対する意識の高まりと、女性のためのヘルスケア拡充に向けた政府の取り組み
• 市場抑制要因
  • 月経困難症治療薬および機器の製品回収に関連する問題
• 市場機会
  • 月経困難症治療の進歩と新薬の出現
  • ウェアラブル技術の採用とデジタルヘルスの普及
• 市場の課題
  • 月経困難症管理に関する社会的障壁とスティグマ化

ポーターの5つの力：月経困難症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：月経困難症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、月経困難症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析月経困難症治療薬市場における競合情勢の把握

月経困難症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス月経困難症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、月経困難症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 月経困難症の有病率と効果的な治療法の必要性
    • 女性の生殖に関する健康に関する意識の高まりと、女性向けヘルスケアの拡大に向けた政府の取り組み
  • 抑制要因
    • 月経困難症治療薬および医療機器の製品リコールに関連する問題
  • 機会
    • 月経困難症治療の進歩と新薬の登場
    • ウェアラブル技術の導入とデジタルヘルスの普及
  • 課題
    • 月経困難症の管理に関する社会的障壁と偏見
• 市場セグメンテーション分析
  • タイプ：原発性月経困難症が広く発生し、痛みの緩和管理が広範囲に必要となる
  • 治療：月経困難症を永久的に緩和するために子宮摘出治療を採用する
  • 流通チャネル：利便性、機密性、医薬品や鎮痛パッチの競争力のある価格設定により、オンライン薬局が好まれる傾向が高まっています。
  • エンドユーザー：アクセスしやすくコスト効率に優れているため、ホームケア分野では月経困難症治療薬の採用が増加しています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 月経困難症治療薬市場：タイプ別

• 原発性月経困難症
• 二次性月経困難症

第7章 月経困難症治療薬市場治療別

• 薬物治療
  • 複合経口避妊薬
  • COX-2阻害剤
  • 非ステロイド性抗炎症薬
  • 市販薬
  • 経皮吸収型グリセリルトリニトレート
• 手術
  • 子宮摘出
  • 子宮内避妊器具
  • 腹腔鏡下子宮仙骨神経切除術
  • レボノルゲストレル子宮内システム（LN-IUS）
  • 仙骨前神経切除術
• 治療薬
  • 代替療法
  • 心理療法

第8章 月経困難症治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 月経困難症治療薬市場：エンドユーザー別

• ホームケア
• 病院
• 専門クリニック

第10章 南北アメリカの月経困難症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の月経困難症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの月経困難症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ミスラ、月経困難症治療薬として日本で販売承認申請
  • チャイム・バイオロジクスとホープ・メディシンが製造契約を締結、子宮内膜症と男性型脱毛症を標的とした初の抗体医薬品HMI-115の発売を加速
  • ミスラ、日本での月経困難症治療薬で富士製薬から250万ユーロを受領
  • 住友製薬とファイザー、カナダでMYFEMBREEのカナダ保健省承認を取得
  • ゲデオン・リヒターと住友製薬、子宮内膜症治療RYEQOについてCHMPの肯定的見解を取得
  • モントリオール発の新技術が生理痛対策に役立つ可能性
  • 中外製薬とバイオフォーミス、子宮内膜症に伴う疼痛に対するデータ駆動型バーチャルケアに重点を置いた新たな提携を締結
  • デア・バイオサイエンス、原発性月経困難症治療の第1相試験を開始
  • ヘルステックのスタートアップ企業Oviraは、薬を使わない生理痛緩和という重要な問題に取り組む女性たちを支援しています。
  • コーラは、美しさにインスパイアされた新しいデザインとウェルネスポートフォリオの拡大により、生理ケアを再考し、誰もが快適に過ごせるようにします。

企業一覧

• Abbott Laboratories
• AA Pharma Inc.
• Cora Life by LYV Life, Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited.
• Merck & Co., Inc.
• AbbVie Inc.
• Alfa Pharma GmbH
• ASKA Pharmaceutical Co., Ltd.
• Bayer AG
• Lupin Pharmaceuticals, Inc.
• Myoovi
• Viatris Inc.
• Myovant Sciences by Sumitovant Biopharma, Inc.
• Sanofi S.A.
• Cumberland Pharmaceuticals Inc.
• GlaxoSmithKline PLC
• Comforte Cream by PMS4PMS, LLC
• Micro Labs Limited
• LGM Pharma
• Dr. Reddy's Laboratories Ltd.
• Gedeon Richter Plc.
• Alvogen, Inc.
• Endo Pharmaceuticals Inc.
• Perrigo Company PLC
• Teva Pharmaceutical Industries Ltd.
• Ovira
• Ferring B.V.
• F. Hoffmann-La Roche AG
• Rael, Inc.
• Novartis AG
• Haleon PLC
• Johnson & Johnson Services, Inc.
• Hikma Pharmaceuticals PLC
• Livia by iPulse Medical Ltd.
• Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. DYSMENORRHEA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. DYSMENORRHEA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DYSMENORRHEA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DYSMENORRHEA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE PILLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OVER-THE-COUNTER MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TRANSDERMAL GLYCERYL TRINITRATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HYSTERECTOMY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LAPAROSCOPIC UTEROSACRAL NERVE ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LEVONORGESTREL INTRAUTERINE SYSTEM (LN-IUS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRESACRAL NEURECTOMY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PSYCHOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 59. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 62. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 63. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 64. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 96. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 99. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 100. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 101. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 103. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 105. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 106. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 107. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 108. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 223. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 225. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 226. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 227. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 228. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 251. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 252. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 253. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 254. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 255. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 256. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 257. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 258. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 259. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 260. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 261. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 262. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 263. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 264. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 326. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 327. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 328. DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 329. DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Dysmenorrhea Treatment Market was valued at USD 7.16 billion in 2023, expected to reach USD 7.80 billion in 2024, and is projected to grow at a CAGR of 8.98%, to USD 13.09 billion by 2030.

The dysmenorrhea treatment market encompasses a range of pharmaceuticals, devices, and alternative therapies aimed at alleviating menstrual pain, which afflicts a substantial segment of the global female population. The necessity for these treatments is driven by the high prevalence of dysmenorrhea and its impact on quality of life, productivity, and mental health. Applications range from over-the-counter pain relievers, such as NSAIDs, to hormonal therapies and novel interventions like transcutaneous electrical nerve stimulation (TENS) and acupuncture. Key end-users include hospitals, clinics, and individual consumers seeking at-home relief options. Market growth is propelled by increasing awareness, improved healthcare access, and advances in biotechnology enabling personalized medicine. A growing interest in non-invasive and alternative medicine further expands the treatment scope. Nevertheless, challenges such as side effects of conventional therapies, lack of awareness in underdeveloped regions, and regulatory hurdles pose significant barriers. Market participants must navigate these limitations while addressing the unmet needs through innovative research into less invasive and more effective solutions, like breakthrough applications in neurostimulation and wearable technology. Governmental policies supporting women's health and rising investment in R&D present robust opportunities. Recommendations for capturing these opportunities include ramping up education efforts, focusing on under-served markets, and fostering collaborations with healthcare providers to expand product reach and endorse trust. Emphasizing the development of side-effect-free treatments through natural or biotechnological means could also capture consumer interest. Insights into the nature of the market reveal a competitive landscape that is evolving with scientific progress, consumer preferences shifting towards holistic health approaches, and a growing emphasis on integrated solutions combining medicinal and technological advancements. Key areas ripe for innovation include digital health integration with real-time monitoring and the exploration of alternative pain management techniques that align with preferences for minimal intervention and enhanced affordability.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dysmenorrhea Treatment Market

The Dysmenorrhea Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of dysmenorrhea and the need for effective treatment options
  • Growing awareness about women's reproductive health and government initiatives to expand healthcare for women
• Market Restraints
  • Issues associated with product recalls for dysmenorrhea drugs and devices
• Market Opportunities
  • Advancements in therapy for dysmenorrhea and the emergence of novel drugs
  • Adoption of wearable technology and the proliferation of digital health
• Market Challenges
  • Societal barriers and stigmatization regarding dysmenorrhea management

Porter's Five Forces: A Strategic Tool for Navigating the Dysmenorrhea Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dysmenorrhea Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dysmenorrhea Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dysmenorrhea Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dysmenorrhea Treatment Market

A detailed market share analysis in the Dysmenorrhea Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dysmenorrhea Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dysmenorrhea Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Dysmenorrhea Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AA Pharma Inc., Cora Life by LYV Life, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited., Merck & Co., Inc., AbbVie Inc., Alfa Pharma GmbH, ASKA Pharmaceutical Co., Ltd., Bayer AG, Lupin Pharmaceuticals, Inc., Myoovi, Viatris Inc., Myovant Sciences by Sumitovant Biopharma, Inc., Sanofi S.A., Cumberland Pharmaceuticals Inc., GlaxoSmithKline PLC, Comforte Cream by PMS4PMS, LLC, Micro Labs Limited, LGM Pharma, Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc., Alvogen, Inc., Endo Pharmaceuticals Inc., Perrigo Company PLC, Teva Pharmaceutical Industries Ltd., Ovira, Ferring B.V., F. Hoffmann-La Roche AG, Rael, Inc., Novartis AG, Haleon PLC, Johnson & Johnson Services, Inc., Hikma Pharmaceuticals PLC, Livia by iPulse Medical Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Dysmenorrhea Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Primary Dysmenorrhea and Secondary Dysmenorrhea.
• Based on Treatment, market is studied across Medication, Surgery, and Therapeutics. The Medication is further studied across Combined Oral Contraceptive Pills, Cox-2 Inhibitors, Non-Steroidal Anti-Inflammatory Drugs, Over-The-Counter Medications, and Transdermal Glyceryl Trinitrate. The Surgery is further studied across Hysterectomy, Intrauterine Device, Laparoscopic Uterosacral Nerve Ablation, Levonorgestrel Intrauterine System (LN-IUS), and Presacral Neurectomy. The Therapeutics is further studied across Alternative Therapies and Psychological Therapies.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of dysmenorrhea and the need for effective treatment options
    • 5.1.1.2. Growing awareness about women's reproductive health and government initiatives to expand healthcare for women
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with product recalls for dysmenorrhea drugs and devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in therapy for dysmenorrhea and the emergence of novel drugs
    • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
  • 5.1.4. Challenges
    • 5.1.4.1. Societal barriers and stigmatization regarding dysmenorrhea management
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management
  • 5.2.2. Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea
  • 5.2.3. Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches
  • 5.2.4. End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dysmenorrhea Treatment Market, by Type

• 6.1. Introduction
• 6.2. Primary Dysmenorrhea
• 6.3. Secondary Dysmenorrhea

7. Dysmenorrhea Treatment Market, by Treatment

• 7.1. Introduction
• 7.2. Medication
  • 7.2.1. Combined Oral Contraceptive Pills
  • 7.2.2. Cox-2 Inhibitors
  • 7.2.3. Non-Steroidal Anti-Inflammatory Drugs
  • 7.2.4. Over-The-Counter Medications
  • 7.2.5. Transdermal Glyceryl Trinitrate
• 7.3. Surgery
  • 7.3.1. Hysterectomy
  • 7.3.2. Intrauterine Device
  • 7.3.3. Laparoscopic Uterosacral Nerve Ablation
  • 7.3.4. Levonorgestrel Intrauterine System (LN-IUS)
  • 7.3.5. Presacral Neurectomy
• 7.4. Therapeutics
  • 7.4.1. Alternative Therapies
  • 7.4.2. Psychological Therapies

8. Dysmenorrhea Treatment Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Dysmenorrhea Treatment Market, by End-Users

• 9.1. Introduction
• 9.2. Homecare
• 9.3. Hospitals
• 9.4. Specialty Clinics

10. Americas Dysmenorrhea Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Dysmenorrhea Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Dysmenorrhea Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Mithra Submits Marketing Approval Application in Japan to Combat Dysmenorrhea
  • 13.3.2. Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
  • 13.3.3. Mithra to Receive EUR 2.5 Million from Fuji Pharma for Dysmenorrhea Treatment in Japan
  • 13.3.4. Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE
  • 13.3.5. Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO for Treatment of Endometriosis
  • 13.3.6. How New Tech from Montreal Could Help the Fight Against Period Cramps
  • 13.3.7. Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
  • 13.3.8. Dare Bioscience Begins Phase I Trial of Primary Dysmenorrhea Therapy
  • 13.3.9. Healthtech Startup Ovira is Helping Women Tackle a Key Problem - Drug-Free Period Pain Relief
  • 13.3.10. Cora Reimagines Period Care with a New Beauty-Inspired Look and Expanded Wellness Portfolio to Make Comfort Accessible for Everyone

Companies Mentioned

• 1. Abbott Laboratories
• 2. AA Pharma Inc.
• 3. Cora Life by LYV Life, Inc.
• 4. Pfizer Inc.
• 5. Takeda Pharmaceutical Company Limited.
• 6. Merck & Co., Inc.
• 7. AbbVie Inc.
• 8. Alfa Pharma GmbH
• 9. ASKA Pharmaceutical Co., Ltd.
• 10. Bayer AG
• 11. Lupin Pharmaceuticals, Inc.
• 12. Myoovi
• 13. Viatris Inc.
• 14. Myovant Sciences by Sumitovant Biopharma, Inc.
• 15. Sanofi S.A.
• 16. Cumberland Pharmaceuticals Inc.
• 17. GlaxoSmithKline PLC
• 18. Comforte Cream by PMS4PMS, LLC
• 19. Micro Labs Limited
• 20. LGM Pharma
• 21. Dr. Reddy's Laboratories Ltd.
• 22. Gedeon Richter Plc.
• 23. Alvogen, Inc.
• 24. Endo Pharmaceuticals Inc.
• 25. Perrigo Company PLC
• 26. Teva Pharmaceutical Industries Ltd.
• 27. Ovira
• 28. Ferring B.V.
• 29. F. Hoffmann-La Roche AG
• 30. Rael, Inc.
• 31. Novartis AG
• 32. Haleon PLC
• 33. Johnson & Johnson Services, Inc.
• 34. Hikma Pharmaceuticals PLC
• 35. Livia by iPulse Medical Ltd.
• 36. Sun Pharmaceutical Industries Ltd.